

Principal Investigator/Program Director (Last, First, Middle): Walker, Ameae M.

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Ameae M. Walker, Ph.D.	POSITION TITLE Professor
--------------------------------	-----------------------------

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Liverpool University, England. Faculty of Science	BSc(Hons)	1973	Biochemistry
Liverpool University, England. Faculty of Medicine	PhD	1976	Cell Biology/Endocrinology
Yale University, New Haven, CT. Medical School	Postdoc	1976-1979	Cell Biology

1979-1986 Assistant Professor of Biomedical Sciences, University of California, Riverside.
1986-1994 Associate Professor of Biomedical Sciences, University of California, Riverside.
1991-1998 Graduate Advisor for Interdepartmental Ph.D. Program in Biomedical Sciences.
1994-present Professor of Biomedical Sciences, University of California, Riverside (currently step VIII).
2005-2010 Chair of the Faculty of Biomedical Sciences
2006-present UCR Distinguished Teaching Professor
2010-2012 Vice Chair of the campus Academic Senate
2012-2014 Chair of the Faculty of the school of Medicine
2014-2020 Campus Vice Provost for Academic personnel
2020-present Professor of the Graduate Division and Emerita Professor of Biomedical Sciences

Teaching experience: Whole career teaching medical cell biology and histology at three institutions (Liverpool and Yale Medical schools and UCR-now part of an integrated disease-based curriculum). More than 30 years as course coordinator, teaching at least half the cell biology/histology lectures (essentially have taught every topic at one time or another) and all labs each year (~120 contact hours/yr until new curriculum instituted in 2004-2005). This course evolved over the years to be very functionally oriented, integrating biochemistry, physiology and disease long before the integrated curriculum. Now also teach pathology of cardiovascular, renal and skeletal systems to first year medical students in the integrated curriculum. Ten years of development and teaching a clinical biochemistry lab course. Fifteen years of coordinating clinical correlates to the basic sciences. In addition to teaching histopathology throughout the new first year integrated medical curriculum, I also coordinated a 13-unit block of instruction in the second year focused on pathophysiology of the endocrine, gastrointestinal and reproductive systems. Development and teaching of a variety of graduate courses,

including the core “Molecular basis of disease” and one undergraduate course entitled “Frontiers in Medicine”. Author of a variety of problem-based learning cases used at current and other institutions. Contributor to graduate stem cell course. Designed original version of the new graduate, disease-based curriculum. See later for research lab-based instruction.

Current Professional Memberships: Endocrine Society, American Association for Cancer Research, American Association of Immunologists.

Honors/Awards: Medical Research Council (England) Predoctoral Fellowship, 1973-1976; Travel award from the Wellcome Trust to enable me to take up postdoctoral position at Yale University, 1976; Faculty Research Lecturer, Kitasato University, Japan, 1993-awarded Kitasato medal; Recipient of Campus Distinguished Teaching Award, 1994—Highest award of the Academic Senate which can only be awarded once to any individual; Faculty marshal at Hippocratic Oath Ceremony, UCLA, 1994—Honor awarded by graduating medical class. Campus service award of merit, 1996; Cancer Federation Research Award, 1997; Keynote Speaker at Japanese Pituitary Society Meeting, 2001. Award for teaching excellence from the MD classes of 2007, 2010, 2011, 2012, 2013, 2016. Elected to the Academy of Distinguished Teachers, 2006. Elected Member (called Fellow) Royal Society of Medicine, 2008. UCR Distinguished Service Award, 2012. California Senate Resolution in honor of my service to the State, 2013. Title of Guest Professor of Jishou University in “Honor of "Outstanding Academic Achievements", 2015; Teaching award from Biomedical Sciences Graduate students, 2017.

Notable Professional Service: DOD Breast Cancer Research Program integration panel member (equivalent to NIH second level of review) 2006, 2009, 2010, 2011, 2012, 2014; Editorial Board of Molecular and Cellular Endocrinology 2005- present; Editorial board of Endocrine 2005- 2010; National Cancer Institute RAID Program Study Section member, 2003, 2004; Elected Chair of 1996 Prolactin Gordon Conference (Vice Chair 1994). Review for many additional journals in multiple fields. CRCC grant evaluation panel, 2008-2009, 2009-2010, 2010-2011(chair). Visiting professor at Universities in Jishou and Xian, China, 2013.

Selected Campus Service not already reflected above (total resulting in Distinguished Service Award, 2012)

Vice chair executive committee for College of Natural and Agricultural sciences, 1985-1986

Chair, various committees for multi-department Endocrinology Postdoctoral Training grant, 1980-1993

Chair, campus charges committee, 1989-1990 and 1991-1992

Chair, campus scholarships and honors, 1996-1997

Director and sole advisor, Interdepartmental Graduate Program in Biomedical Sciences, 1991-1998

Chair, excellence review committee (equivalent of committee on academic personnel for lecturers), 1996-1997 and 2001-2002

Chair, multiple faculty search committees
Chair, pre-professional health sciences committee 2000-2005
Chair, campus committee on academic personnel, 2004-05 (member previous two years)
Chair, senate Ad Hoc committee on faculty advancement, 2005-2007
Member, academic planning group for medical school, 2006-2008
Chair, search committee for founding dean of Medical School, 2008
Co-Chair, search for director of Health Sciences Research Institute, 2006-2008
Chair, campus shadow committee on academic personnel 2007-2008 and 2008-2009
Chair, search for Vice Provost for academic personnel, 2009-2010
Chair, LCME accreditation committees, 2010-2011, 2011-2012 and in 2003-2004 and 1997-1998
Member, Medical School admissions, 1981-2010
Member and local coordinator, MD thesis committee, 1989-2005
Member, search committee for EVC and Provost, 2009-2011, and 2013.
Member LCME accreditation committees (2) 2015-2016

Publications

Technical Journal Articles - Refereed

1. Walker, A.M. and Hopkins, C.R. Dissociation of the porcine anterior pituitary. The kinetics of luteinising hormone release in response to luteinising hormone-releasing hormone. Mol. Cell. Endocrinol. 12: 177-187, 1978.
2. Walker, A.M. and Hopkins, C.R. Stimulation of luteinising hormone release by luteinising hormone-releasing hormone in the Porcine anterior pituitary: The role of cyclic AMP. Mol. Cell. Endocrinol. 10: 327-341, 1978.
3. Hopkins, C.R. and Walker, A.M. Calcium as a second messenger in the stimulation of luteinising hormone secretion. Mol. Cell. Endocrinol. 12: 189-208, 1978.
4. Walker, A.M. and Farquhar, M.G. Preferential release of newly synthesized prolactin granules is the result of functional heterogeneity among mammatrophs. Endocrinology 107: 1095-1105, 1980.
5. Cross, M. and Walker, A.M. Physiological concentrations of L-leucine control release of prolactin from cultured rat pituitary cells. Endocrinology 114: 80-86, 1984.
6. Conconi, M.V. and Walker, A.M. Chloroquine affects prolactin secretion and Golgi morphology in the mammatroph. Endocrinology 114: 725-734, 1984.
7. Kadowaki, J., Ku, N., Oetting, W.S. and Walker, A.M. Mammatroph autoregulation: Uptake of secreted prolactin and inhibition of secretion. Endocrinology 114: 2060-2067, 1984.
8. Giss, B.J. and Walker, A.M. Mammatroph autoregulation: Intracellular fate of internalized prolactin. Mol. Cell. Endocrinol. 42: 259-267, 1985.

9. Oetting, W.S. and Walker, A.M. Intracellular processing of prolactin. Endocrinology 117: 1565-1570, 1985.
10. Oetting, W.S., Tuazon, P.T., Traugh, J.A. and Walker, A.M. Phosphorylation of prolactin. J. Biol. Chem. 261: 1649-1652, 1986.
11. Miller, N., Smith, P.A. and Walker, A.M. Increased dietary leucine changes the rhythm of prolactin secretion. Metabolism 35: 622-626, 1986.
12. Walker, A.M. Specific and reversible degranulation of pituitary mammothrophs. Mol. Cell. Endocrinol. 47: 71-80, 1986.
13. Oetting, W.S. and Walker, A.M. Differential isoform distribution between stored and secreted PRL. Endocrinology 119: 1377-1381, 1986.
14. Oetting, W.S., Ho, T.W.C., J.R. Greenan and Walker, A.M. Production and secretion of the 21-23.5 Kd prolactin-like molecules. Mol. Cell. Endocrinol. 61: 189-199 (1989).
15. Ho, T.W.C., Greenan, J.R. and Walker, A.M. Mammothroph autoregulation: The differential roles of the 24 Kd isoforms of prolactin. Endocrinology 124: 1507-1514 (1989).
16. Walker, A.M., Robertson, M.T. and Jones, C.J. Distribution of a prolactin-like material in human eccrine sweat glands. J. Invest. Dermatol. 93: 50-53 (1989).
- 16a. Reprinted in Clinical Digest Series, 1990.
17. Greenan, J.R., Balden, E., Ho, T.W.C. and Walker, A.M. Biosynthesis of the secreted 24 kd isoforms of prolactin. Endocrinology 125: 2041-2048 (1989).
18. Greenan, J.R., Lorenson, M.Y., Conconi, M.V. and Walker, A.M. Alterations in *in Situ* prolactin secretory granule morphology and immunoactivity by thiols and divalent cations. Endocrinology, 126: 512-518, 1990.
19. Joe, T.L. and Walker, A.M. Maternal dietary leucine supplementation affects apparent lactational activity and pup development in rats. J. Nutr. Sci. Vitamol. 36: 609, 1991.
20. Balden, E., Walker, A.M. and Cukierman, S. Reconstitution of single calcium channels from secretory granules of rat adenohypophysis in planar lipid membranes. Mol. Cell. Endocrinol. 77: 85-90, 1991.
21. Ho, T.W.C., Balden, E., Chao, J. and Walker, A.M. Prolactin (PRL) processing by kallikrein: Production of the 21-23.5 K PRL-like molecules and inferences about PRL storage in mature secretory granules. Endocrinology 129: 184-192, 1991.
22. Wang, Y.-F., H. Jia, A.M. Walker and S. Cukierman. K-current mediation of prolactin-induced proliferation of malignant (Nb2) lymphocytes. J. Cell. Physiol. 152: 185-189 (1992).

23. Krown, K.A., Y.-F. Wang, T.W.C. Ho, P.A. Kelly and A.M. Walker. Prolactin isoform 2 as an autocrine growth factor for GH₃ cells. Endocrinology 131: 595-602 (1992).
24. Langford, C.A., J. Kadowaki and A.M. Walker. In vitro glucoregulation of prolactin secretion. Neuroendocrinology, 56: 838-844 (1992).
25. Walker, A.M., C.A. Peabody, T.W.C. Ho and M.D. Warner. 50 Kd prolactin binding protein in schizophrenics on neuroleptic medication. J. Psychiatry and Neurosciences 17: 61-68 (1992).
26. Ho, T.W.C., F.-S. Leong, C.H. Olaso and A.M. Walker. Secretion of specific non-phosphorylated and phosphorylated rat prolactin isoforms at different stages of the estrous cycle. Neuroendocrinology 58: 160-165, (1993).
27. Wang, Y.-F. and Walker, A.M. Dephosphorylation of standard prolactin produces a more biologically active molecule. Evidence for antagonism between non-phosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation. Endocrinology 133: 2156-2160 (1993).
28. Ho, T.W.C., Kawaminami, M. and Walker, A.M. Secretion of phosphorylated and non-phosphorylated monomer prolactin isoforms during rat pregnancy and pseudopregnancy. Endocrine. J. 1: 435-439 (1993).
29. Krown, K.A., Wang, Y.F. and Walker, A.M. Autocrine interaction between prolactin and its receptor occurs intracellularly in the 235-1 mammotroph cell line. Endocrinology 134: 1546-1552 (1994).
30. Kawaminami, M., Uchida, S., Marumoto, N., Naito, K., Okazaki, K., Sato, Y., Kurusu, S., Hashimoto, I., Mutoh, K.-I, and Walker, A.M. Stimulation of secretion by membrane depolarization increases extracellular plasma membrane association of annexin 5 in the anterior pituitary gland. Endocrine J. 2: 357-362 (1994).
31. Baker, M.A., Dawson, D.D., Peters, C.E. and Walker, A.M. Effects of estrogen on thermoregulatory evaporation in rats exposed to heat. Am. J. Physiol. 267: R673-R677 (1994).
32. Zimering, M.B., Riley, D.J., Tahkker Varia, S., Walker, A.M., Lakshminaryan, V., Shah, R., Brandi, M.L., Ezzat, S., Katsumata, N., Friesen, H.G., Max, S.J. and Eng, J. Circulating fibroblast growth factor-like autoantibodies in multiple endocrine neoplasia type I: relation to prolactinoma. J. Clin. Endo. Metab. 79: 1546-1552 (1994).
33. Walker, A.M., Montgomery, D.W., Suraiya, S., Ho, T.W.C., Garewal, H.S., Wilson, J. and Lorand, L. Prolactin-immunoglobulin G complexes from human serum act as co-stimulatory ligands causing proliferation of malignant B lymphocytes. PNAS USA 92: 3278-3282 (1995).
34. Wang, Y.-F., Liu, J.-W., Mamidi, M. and Walker, A.M. Identification of the major site of rat prolactin phosphorylation as serine 177. J. Biol. Chem. 271: 2462-2469 (1996).

35. Lorenson, M.Y., Patel, T., Liu, J.-W. and Walker, A.M. Prolactin (PRL) is a zinc binding protein I. Zinc interactions with monomeric PRL and divalent cation protection of intragranular PRL cysteine thiols. Endocrinology 137: 809-816 (1996).
36. Lorenson, M.Y., Liu, M.-W., Patel, T. and Walker, A.M. Intragranular prolactin phosphorylation and kallikrein cleavage are regulated by zinc and other divalent cations. Endocrine 4: 244-257 (1996).
37. Kawaminami, M., Okazaki, K., Uchida, S., Maramuto, N., Kurusu, S., Hashimoto, I., Takehara, K. and Walker, A.M. Annexin 5: Intrapituitary distribution and effects on prolactin release. Endocrine 5: 9-14 (1996).
38. Liu, J.-W., Dawson, D.D., Peters, C.E., Baker, M.A. and Walker, A.M. Estrogen replacement in ovariectomized rats results in physiologically significant levels of circulating progesterone and, co-administration of progesterone markedly reduces the circulating estrogen. Endocrine 6: 125-131 (1997).
39. Chen, T.J., Kuo, C.-Y.B., Tsai, K.F., Liu, J.-W., Chen, D.-Y. and Walker, A.M. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 139: 609-616 (1998).
40. Coss, D., Kuo, C.-Y.B., Yang, L., Ingleton, P., Luben, R. and Walker, A.M. Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin. Endocrinology 140: 5087-5094, 1999.
41. Coss, D., Yang, L., Kuo, C.B., Xu, X., Luben, R.A. and Walker, A.M. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am. J. Physiol. Endocrinol. Metab. 279: E1216-E1225, 2000.
42. Yang, L., Kuo, C.B., Liu, Y., Coss, D., Xu, X., Chen, C., Oster-Granite, M.L. and Walker, A.M. Administration of unmodified prolactin (U-PRL) and a molecular mimic of phosphorylated prolactin (PP-PRL) during rat pregnancy provides evidence that the U-PRL:PP-PRL ratio is crucial to the normal development of pup tissues. J. Endocrinol. 168: 227-238, 2001.
43. Bridges, R., Rigerio, B., Byrnes, E., Yang, L. and Walker, A.M. Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed nulliparous female rats. Endocrinology 142: 730-739, 2001.
44. Warner, M.D., Walker, A.M., D'Souza, D.C., Lee, D., Nasser, D. and Peabody, C.A. Lower prolactin bioactivity in unmedicated schizophrenic patients. Psychiatry Res. 102: 249-254, 2001.
45. Xu, X., Kreye, E., Kuo, C.B. and Walker, A.M. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Cancer Res. 61: 6098-6114, 2001.
46. Tuazon, P.T., Lorenson, M.Y., Walker, A.M. and Traugh, J.A. p21-activated protein kinase gamma-PAK in pituitary secretory granules phosphorylates prolactin. FEBS Lett. 515: 84-88, 2002.

47. Kuo, C.B., Wu, W., Xu, X., Yang, L., Chen, C., Coss, D., Birdsall, B., Nasser, D. and Walker, A.M. Pseudophosphorylated prolactin (S179D PRL) inhibits growth and promotes beta-casein gene expression in the rat mammary gland. Cell Tissue Res. 309: 429-437, 2002.
48. Budge, H., Mostyn, A., Wilson, V., Khong, A., Walker, A.M., Symonds, M.E. and Stephenson, T. The effect of maternal prolactin infusion during pregnancy on fetal adipose tissue development. J. Endocrinol. 174: 427-433, 2002.
49. Xu, X., Wu, W., Williams, V., Khong, A., Chen, Y.-H., Deng, C. and Walker, A.M. Opposite effects of unmodified prolactin on morphology and the expression of prostate-specific genes in the normal rat prostate. Prostate 54: 1-9, 2002.
50. Yang, L., Lii, S., Kuo, B., Buckley, A., Buckley, D., Chen, C., Xu, X., Coss, D. and Walker, A.M. Maternal prolactin composition can permanently affect epidermal $\gamma\delta$ T cell function in the offspring. Dev. Compar. Immunol. 26:849-860, 2002.
51. Johnson TE, Vue M, Brekhuis S, Khong A, Ho TWC, Walker AM. Unmodified prolactin (PRL) promotes PRL secretion and acidophil hypertrophy and is associated with pituitary hyperplasia in female rats. Endocrine (special edition on prolactin) 20: 101-110, 2003.
52. Wu W, Coss D, Lorenson MY, Kuo CB, Xu X, Walker AM. Different Biological Effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry 42: 7561-7570, 2003
53. Schroeder MD, Brockman JL, Walker AM, Schuler LA. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D PRL. Endocrinology 144: 5300-5307, 2003
54. Huang KT, Chen YH, Walker AM. Inaccuracies in MTS assays: major distorting effects of medium, serum albumin, and fatty acids. Biotechniques 37: 406-412, 2004
55. Pearce S, Budge H, Mostyn A, Generver E, Webb R, Ingleton P, Walker AM, Symonds ME, Stephenson T. Prolactin, the prolactin receptor and uncoupling protein abundance and function in adipose tissue during development in young sheep. J. Endocrinol. 184: 351-359, 2005
56. Tan D, Johnson DA, Wu W, Zeng L, Chen YH, Chen WY, Vonderhaar BK, Walker AM. Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short PRL receptors in living human cells. Mol Endocrinol. 19: 1291-1303, 2005
57. Naylor MJ, Oakes SR, Gardiner-Garden M, Harris J, Blazek K, Ho TWC, Li FC, Wynick D, Walker AM, Ormandy CJ. Transcriptional changes underlying the secretory activation phase of mammary gland development. Mol Endocrinol. 19: 1868-1883, 2005

58. Wu W, Ginsburg E, Vonderhaar BK, Walker AM. S179D prolactin increases vitamin D receptor and p21 through upregulation of short 1b prolactin receptor in human prostate cancer cells. *Cancer Research* 65: 7509-7515, 2005.
59. Wu W, Walker AM. Human chorionic gonadotropin β (HCG β) downregulates E-cadherin and promotes prostate cancer cell migration and invasion. *Cancer* 106:68-78, 2006
60. Guzman EA, Chen YH, Langowski JL, De Guzman, A, Lo H-L, Walter B, Muller HK, Walker AM, Owen LB. Abrogation of Delayed Type Hypersensitivity Responses to *Candida Albicans* Produced by a Molecular Mimic of Phosphorylated Prolactin. *J Neuroimmunology* 170: 31-40, 2005.
61. Langenheim JF, Tan D, Walker AM, Chen W. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. *Mol Endocrinol* 20:661-674, 2006
62. Ma LJ, Guzman EA, DeGuzman A, Walter B, Muller HK, Walker AM and Owen LB. Unexpected effects of UVB in IL-10 transgenic mice: normalization of contact hypersensitivity response. *Arch Derm Res* 297: 417-420, 2006
63. Ueda E, Ozerdem U, Chen YH, Yao M, Huang KT, Sun H, Martins-Green M, Bartolini P, Walker AM A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. *Endocrine Related Cancer* 13: 95-111, 2006
64. Wu W, Chen YH, Ueda E, Tan D, Bartolini P, Walker AM. Different Forms of Prolactin have Opposing Effects on the Expression of Cell Cycle Regulatory Proteins in Differentiated Mammary Epithelial Cells. *Oncology Research* 16: 75-84, 2006
65. Soares CRJ, Glezer A, Okazaki K, Ueda EKM, Heller SR, Walker AM, Goffin V, Bartolini P. Physico-chemical and biological characterizations of two human prolactin analogs exhibiting controversial bioactivity, synthesized in Chinese hamster ovary (CHO) cells. *Protein Expression and Purification* 48: 182-194, 2006
66. Ueda E, Lo H-L, Bartolini P, Walker AM. S179D prolactin (PRL) primarily uses the extrinsic pathway and MAPkinase signaling to induce apoptosis in human endothelial cells. *Endocrinology* 147: 4627-4637, 2006
67. Wang Y, Chiu C, Nakamura T, Walker AM, Petridou B, Trousdale M, Hamm-Alvarez S, Schechter J, Mircheff A. Elevated Prolactin Redirects Secretory Vesicle Traffic in Rabbit Lacrimal Acinar Cells. *Am J Physiol*, 292: E1122-1134, 2006
68. Ma LJ, Guzman EA, DeGuzman A, Muller HK, Walker AM, Owen LB. Local cytokine levels associated with delayed type hypersensitivity responses: modulation by gender, ovariectomy and estrogen replacement. *J Endocrinol*, 193: 291-297, 2007

69. Wu W, Zanello L, Walker AM. S179D Prolactin Sensitizes Human Prostate Cancer Cells such that Physiological Concentrations of 1, 25 dihydroxy Vitamin D 3 result in Growth Inhibition and Cell Death. *Prostate* 67: 1498-1506, 2007
70. Nephew, B.C., Amico, J., Cai, H.M., Walker, A.M., Bridges, R.S. Intracerebroventricular administration of the prolactin receptor antagonist, S179D PRL, disrupts parturition in rats. *Reproduction* 134: 155-160, 2007.
71. Wang, Y; Chiu, CT.; Nakamura, T; Walker, AM.; Petridou, B; Trousdale, MD; Hamm-Alvarez, SF; Mircheff, AK; Schechter, JE. Traffic of endogenous, transduced, and endocytosed prolactin in rabbit lacrimal acinar cells. *Exp Eye Res.* 85:749-761, 2007.
72. Guzman E A, Langowski JL, DeGuzman A, Muller HK, Walker AM, Owen LB. S179D prolactin diminishes the effects of UV light on epidermal gamma Delta T cells. *Mol Cell Endocrinol*, 280:6-12, 2008 Epub 2007
73. Williams VL, DeGuzman A, Dang H, Kawaminami M, Ho TWC, Carter DG, Walker AM. Common and specific effects of the two major forms of prolactin (PRL) in the rat testis. *Am J Physiol* 293: E1795-1803, 2007
74. Tan D, Huang KT, Ueda E, Walker AM. S2 deletion variants of human prolactin receptors demonstrate that extracellular domain conformation can alter conformation of the intracellular signaling domain. *Biochemistry* 47: 479-489, 2008 Epub 2007
75. Ma LJ, Walter B, DeGuzman A, Muller HK, Walker AM. Trans-epithelial Immune Cell Transfer during Suckling Modulates Delayed-Type Hypersensitivity in Recipients as a Function of Gender *PLoSone*, 3: e3562, 2008
76. Deng C, Ueda E, Chen KE, Bula C, Norman AW, Luben RA, Walker AM Prolactin Blocks Nuclear Translocation of VDR by regulating its interaction with BRCA1 in Ros 17/2.8 Osteosarcoma Cells. *Mol Endocrinol.* 23: 226-236, 2009. E pub Dec 12th, 2008
Featured in *Endocrine News* (monthly magazine from Endocrine Society)
77. Helena CV, McKee DT, Bertram R, Walker AM, Freeman ME. The rhythmic secretion of mating-induced prolactin secretion is controlled by prolactin acting centrally. *Endocrinology* 150:3245-3251, 2009
78. Chen Y, Huang KT, Chen KE, Walker AM. Prolactin and Estradiol Utilize Distinct Mechanisms to Increase Serine-118 Phosphorylation and Decrease Levels of Estrogen Receptor α in T47D Breast Cancer Cells. *Breast Cancer Res Treat*, Epub April 18th, 2009 2010 Apr;120(2):369-77.

79. Ueda EKM, Soares C, Bartolini P, DeGuzman A, Lorenson MY, Walker AM. A molecular mimic of phosphorylated prolactin (S179D PRL) secreted by eukaryotic cells has a conformation with increased positive surface charge compared to unmodified prolactin. *Biochemistry* 48:6887-6897, 2009.
80. Huang KT, Walker AM. Long Term Increased Expression of the Short Form 1b Prolactin Receptor in PC-3 Human Prostate Cancer Cells Decreases Cell Growth and Migration, and Causes Multiple Changes in Gene Expression Consistent with Reduced Invasive Capacity. *Prostate* in press 2009, Epub Sept 8th 70(1):37-47, 2010
- 80A. Featured in *UrologyToday*, an online journal Dec 3rd, 2009. www.urotoday.com
81. Tan D, Walker AM. Short Form 1b Human Prolactin Receptor Down-Regulates Expression of the Long Form. *J Molecular Endocrinology* 44: 187-194, 2010 ePub Nov 11, 2009.
82. Yasuhiro Terasaki, Kinno Suke Yahiro, Gustavo Pacheco-Rodriguez, Wendy K. Steagall, Mario P. Stylianou, Jilly F. Evans, Ameae M. Walker, Joel Moss. Effects of Prolactin on TSC2-null Eker Rat Cells and in Pulmonary Lymphangiomyomatosis (LAM). *American Journal of Respiratory and Critical Care Medicine*, 182(4):531-9. Epub 2010 Apr 22.
83. Yang NY, Lopez-Bergami P, Goydos JS, Yip D, Walker AM, Pasquale EB, Ethell IM The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand. *Pigment Cell Melanoma Res.* 2010 Oct;23(5):684-7. Epub 2010 Jul 23.
84. Tan D, Chen KE, Khoo T, Walker AM. Prolactin increases survival and migration of ovarian cancer cells: Importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists. *Cancer Lett.* 2011 Nov 1;310(1):101-8. Epub 2011 Jun 25
85. Eric K Ueda¹, KuangTzu Huang¹, Virginia Nguyen¹, Marco Ferreira² and Ameae M. Walker^{1*} Distribution of prolactin receptors suggests an intraductal role for prolactin in the mouse and human mammary gland, a finding supported by analysis of signaling in polarized monolayer cultures. *Cell Tissue Res.* 2011 Nov;346(2):175-89. Epub 2011 Nov 12
86. Mary Y. Lorenson*, Eric K. Ueda, KuanHui E. Chen, and Ameae M. Walker A Major Prolactin Binding Complex on Human Milk Fat Globule Membranes Contains Cyclophilins A and B: The Complex is Not the Prolactin Receptor. *Am J Physiol* 302(5):E585-94, 2012.

87. Bahmani B, Lytle CY, Walker AM, Gupta S, Vullev VI, Anvari B. Effects of nanoencapsulation and PEGylation on biodistribution of indocyanine green in healthy mice: quantitative fluorescence imaging and analysis of organs. *Int J Nanomedicine*. 2013;8:1609-20. doi: 10.2147/IJN.S42511. Epub 2013 Apr 22
88. T. Morales^{*}, M. Lorenson, A.M. Walker, E. Ramos. Both prolactin (PRL) and a molecular mimic of phosphorylated PRL, S179D-PRL, protect the hippocampus of female rats against excitotoxicity. *Neuroscience*. 2014 Jan 31;258:211-7. In press Nov 16th, 2013
89. DUN-Yong Tan ; Jie Zhang ; Pei-Zhi Tang ; Jian-Jun Huang ; Ameae Walker. Association of D5 Stat5a Induced Breast Cancer Cell Migration with Increased H3K27 Trimethylation and Down-Regulated Expression of E-Cadherin Gene . *Adaptive Medicine* 5 (4) 189-195, 2013.
90. Tan D, Tang P, Huang J, Zhang J, Zhou W, Walker AM. Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer. *Chin Med J (Engl)*. 2014;127(6):1077-83
91. Tan D, Chen KE, Deng C, Tang P, Huang J, Mansour T, Luben RA, Walker AM. An N-terminal splice variant of human stat5a that interacts with different transcription factors is the dominant form expressed in invasive ductal carcinoma. *Cancer Letters*. 2014 Apr 28;346(1):148-57. 2013 Dec 30. [Epub ahead of print]
92. Huang KT, Tan D, Chen KH, Walker AM. Blockade of estrogen-stimulated proliferation by a constitutively-active prolactin receptor having lower expression in invasive ductal carcinoma. *Cancer Lett*. 2015 Mar 28;358(2):152-60.
93. David CN, Frias ES, Elix CC, McGovern KE, Walker AM, Eichler JF, Wilson EH. Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma. *ASN Neuro*. 2015 Jan-Feb;7(1). doi: 10.1177/1759091415572365
94. Tomohiro Yonezawa^{a,b,†}, Kuan-Hui (Ethan) Chen^a, Mrinal K. Ghosh^a, Lorena Rivera^a, Riva Dill^a, Lisa Ma^a, Pedro A. Villa^a, Mitsumori Kawaminami^b, and Ameae M. Walker^a Anti-metastatic Outcome of Isoform-Specific Prolactin Receptor Targeting in Breast Cancer. *Cancer Letters* 2015 Sep 28;366(1):84-92.
95. Chen KH, Walker AM Prolactin inhibits a major tumor-suppressive function of wild type BRCA1. *Cancer Lett*. 2016 Jun 1;375(2):293-302
96. Ghosh MK, Nguyen V, Muller HK, Walker AM Maternal Milk T Cells Drive Development of Transgenerational Th1 Immunity in Offspring Thymus. *J Immunol*. 2016 Sep 15;197(6):2290-6.
97. Riva Dill and Ameae M. Walker. Role of Prolactin in Promotion of Immune Cell Migration into the Mammary Gland. *J Mammary Gland Biol and Neoplasia*. 2017 Mar;22(1):13-26.

98. Kuan-Hui Ethan Chen, Karissa Bustamante, Vi Nguyen, Ameae M. Walker. Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol. *Oncotarget*. 2017 May 30;8(22):36368-36382.
99. Ghosh MK, Muller HK, Walker AM. Lactation-Based Maternal Educational Immunity Crosses MHC Class I Barriers and Can Impart Th1 Immunity to Th2-Biased Recipients. *J Immunol*. 2017 Sep 1;199(5):1729-1736.
100. Lopez T, Chuan C, Ramirez A, Chen KE, Lorensen MY, Benitez C, Mustafa Z, Pham H, Sanchez R, Walker AM, Ge X. Epitope-specific affinity maturation improved stability of potent protease inhibitory antibodies. *Biotechnol Bioeng*. 2018 Nov;115(11):2673-2682. doi: 10.1002/bit.26814.
101. Chen KE, Chen C, Lopez T, Radecki KC, Bustamante K, Lorensen MY, Ge X, Walker AM. Use of a novel camelid-inspired human antibody demonstrates the importance of MMP-14 to cancer stem cell function in the metastatic process. *Oncotarget*. 2018 Jun 29;9(50):29431-29444. doi: 10.18632/oncotarget.25654
102. Dill-Garlow R, Chen KE, Walker AM. Sex Differences in Mouse Popliteal Lymph Nodes. *Sci Rep*. 2019 Jan 30;9(1):965. doi: 10.1038/s41598-018-37175-5.
103. Mary Y Lorensen, Kuan-Hui Ethan Chen, Ameae M Walker Enzyme-linked oligonucleotide hybridization assay for direct oligo measurement in blood. *Biology Methods and Protocols*, Volume 4, Issue 1, 2019, bpy014, <https://doi.org/10.1093/biomethods/bpy014>
104. Christopher T. Holland, Joffrey Hsu, Ameae M. Walker. S179D Prolactin Sensitizes Human PC3 Prostate Cancer Xenografts to Anti-tumor Effects of Well-Tolerated Doses of Calcitriol. *J Cancer Science and Clinical Therapy*. 4: 424-438,2020.
105. Mrinal K. Ghosh, Kuan-hui E. Chen, Riva Dill-Garlow, Lisa J. Ma, Tomohiro Yonezawa, Yuichiro Itoh, Lorena Rivera, Kelly C. Radecki, Quiming P. Wu, Arthur P. Arnold, H. Konrad Muller, Ameae M. Walker. Sex Differences in the Immune System Become Evident in the Perinatal Period in the Four Core Genotypes Mouse. *Front Endocrinol (Lausanne)* 2021; 12: 582614.
106. Kuan-Hui Ethan Chen, Mrinal Ghosh, Lorena Rivera, Samuel Lin, Anil Kumar, Srividya Swaminathan, Mary Y. Lorensen, Ameae M. Walker. Prolactin enhances T regulatory cell promotion of breast cancer through the long form prolactin receptor. *Transl Oncol*. 2021 Nov; 14(11): 101195.
107. Jayakumar P, Martínez-Moreno CG, Lorensen MY, Walker AM, Morales T. Prolactin Attenuates Neuroinflammation in LPS-Activated SIM-A9 Microglial Cells by Inhibiting NF- κ B Pathways Via ERK1/2. *Cell Mol*

- Neurobiol. 2021 Apr 5. doi: 10.1007/s10571-021-01087-2. Epub ahead of print. PMID: 33821330.
108. Radecki KC, Lorensen MY, Carter DG, Walker AM. Microdissection and Dissociation of the Murine Oviduct: Individual Segment Identification and Single Cell Isolation. *J Vis Exp.* 2021 Nov 4;(177).
 109. Ariel DeGuzman, Mary Y. Lorensen and Ameae M. Walker. Bittersweet: relevant amounts of the common sweet food additive, glycerol, accelerate the growth of PC3 human prostate cancer xenografts. *BMC Res Notes* 15: 101 (2022)
 110. Kelly C. Radecki, Matthew J. Ford, Hollian R. Phillipps, Mary Y. Lorensen, David R. Grattan, Yojiro Yamanaka, and Ameae M. Walker. Multiple Cell Types in the Oviduct Express the Prolactin Receptor. *Faseb BioAdv.* Apr 15;4(7):485-504. doi: 10.1096, 2022
 111. Yi-Ling Chen, AKaychia T. Lowery, Samuel Lin, Ameae M. Walker, Kuan-Hui E. Chen. Tumor Cell-Derived Asymmetric Dimethylarginine Regulates Macrophage Functions and Polarization. *Cancer Cell International.* 22: 351, 2022. doi: 10.1186/s12935-022-02769-7
 112. Sadie Barbee, Kelly C. Radecki, Mary Y. Lorensen, and Ameae M. Walker. A Cautionary Tale: Alien prolactins may induce lesser, no, or opposite effects to homologous hormone! *J Neuroendocrinology.* 2022 Dec 10:e13225. doi: 10.1111/jne.13225.
 113. Taghi Khani A, Kumar A, Sanchez Ortiz A, Radecki KC, Aramburo S, Lee SJ, Hu Z, Damirchi B, Lorensen MY, Wu X, Gu Z, Stohl W, Sanz I, Meffre E, Müschen M, Forman SJ, Koff JL, **Walker AM**, Swaminathan S. Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms. *Commun Biol.* 2023 Mar 20;6(1):295. doi: 10.1038/s42003-023-04667-8. PMID: 36941341; PMCID: PMC10027679.

Invited Reviews – Refereed

1. Walker, A.M. Breast carcinoma. In autocrine growth factor and solid tumor malignancy. Walsh, J.H., moderator. Karnes, W.E., Cuttitta, F. and Walker, A.M., discussants. Western J. Med. 155: 156-158, 1991.
2. Walker, A.M. Autocrine regulation of pituitary tumor growth and secretion by prolactin isoforms. In autocrine growth factors and solid tumor malignancy. Walsh, J.H., moderator. Karnes, W.E., Cuttitta, F. and Walker, A.M., discussants. Western J. Med. 155: 159-160, 1991.
3. Walker, A.M. Phosphorylated and non-phosphorylated prolactin isoforms. Trends Endo and Metab. 5: 195-200 (1994).
4. Kuo, C.-Y.B., Coss, D. and Walker, A.M. Prolactin receptor antagonists. Endocrine 9: 121-131 (1998).
5. Walker, A.M. Unmodified and phosphorylated prolactin and gamma delta T cell development and function. Lupus 10: 735-741, 2001.

6. Walker AM. Prolactin Receptor Antagonists. *Current Opin Investigational Drugs* 6: 378-385, 2005
7. Walker, A.M. Therapeutic potential of S179D prolactin - from prostate cancer to angioproliferative disorders: The first selective prolactin receptor modulator. *Expert opinion on Investigational Drugs*, 15: 1257-1267, 2006
8. Walker, A.M. S179D Prolactin: Antagonistic Agony. *Mol Cell Endocrinol*. 276:1-9, 2007
9. KuangTzu Huang, Eric Ueda, YenHao Chen and Ameae M. Walker. Paradigm shifters: Phosphorylated prolactin and short prolactin receptors. *Journal of Mamm Gland Biol and Neoplasia* 13: 69-79, 2008

Invited Reviews – Non Refereed

1. Walker, A.M., Ho, T.W.C., Wang, Y.-F. and Krown, K.A. Autocrine regulation of secretion and cell proliferation in pituitary prolactin cells. In: *Proceedings of the 13th UC Riverside-Nichols Institute Symposium*. Henry, H.H. and Norman, A.W., eds., pp. 101-111, 1991.

Review –Refereed

1. Gupta, P. and Walker, A.M. Protein kinase inhibitors and activators: specificity and mode of action. *J. Basic and Applied Biomedicine* 2: 1-12 (1994).

Chapters

1. Lorenson, M.Y. and Walker, A.M. Structure-function relationships in prolactin. In *Prolactin*, edited by Horseman, N.D. Kluwer Academic Publishers, Massachusetts, 2001, pp. 181-283.
2. KuanHui E Chen and Ameae M. Walker. Potential roles of microRNA 106a in breast cancer. In *Breast Cancer: Carcinogenesis, cell growth and signaling pathways*. Intech 2011. <http://www.intechopen.com/articles/show/title/potential-roles-of-mir-106a-in-breast-cancer>
3. Wei Wu, Changhui Deng, Jennifer L. Brockman, Linda A. Schuler and Ameae M. Walker. Pseudophosphorylated Prolactin: Enhanced Transcription and Message Stabilization. DOI: 10.5772/intechopen.101256. <https://www.intechopen.com/online-first/superior-stimulation-of-casein-mrna-accumulation-by-pseudophosphorylated-prolactin-enhanced-transcri>

Invited Editorial

1. KuanHui E. Chen and Ameae M. Walker. Splice modulating oligomers as cancer therapeutics. *Genes and Cancer* 13:46-48, 2022

Patents

1. Ameae Walker

UC Case No. 1996-166-2

Title: “Prolactin antagonists and uses thereof”

Status: Patent Issued 5/10/2005 US # 6,890,738

2. Kuan-Hui Chen, Tomohiro Yonezawa, Mrinal Ghosh and Ameae Walker

UC Case No. 2012-794-1/2

Title: “Splice modulating oligonucleotides that inhibit cancer”

Status: International application issued 2/18.

3. Ameae M. Walker and Mary Y Lorenson. Title: “methods for detecting oligonucleotides in a sample”. Filing was 6/6/2016. Currently still active.

4. Methods for Treating and Preventing B Cell Disorders. UC case 2021-849. Patent application filed 11/2/2021

- 5.

Graduate Students and postdocs supervised as major professor (not including masters students – note no PhD grad program before 89)

Graduate students and their current position

Yu-Fen Wang (89-93) Vice President for quality control, formally senior research scientist, Wyeth Ayerst

Chiaoyun (Benson) Kuo (94-99), Associate Director, International Center of Regulatory Science, USC

Shigeo Takamori (visiting grad student) Professor, Doshisha University, Kyoto, Japan

Djurdjica Coss (95-00) Full professor, UCR

Lili Yang (97-99), postdoc and lab director at Cal tech, now Assoc Professor, UCLA

XiaoLei Xu (97-01) Manager Regulatory Affairs, Dako (previously at Siemens)

YenHao Chen (01-06) was Assistant Professor, Medical College of Georgia, Augusta, GA now in Biotech, San Francisco area

Changhui Deng (01-06) Assoc Professor, University of California, San Francisco

Eric Ueda –visiting grad student (03-05)-also see postdoc, Assistant Professor, Sao Paulo, Brazil. Current position unclear.

Valencia Williams (01-Dec 06), Associate Professor, West Coast University

Lisa Ma (02-07)– postdoc at Baylor, scientist at UCSD/Scripps, Scientist at ebiosciences, San Diego

KuangTzu (Mark) Huang (02-08)- Assoc Professor, Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Taiwan.

Kuan-Hui Chen (Ethan) (06-11) – was postdoc then Project Scientist, UCR, now tenure-track Assistant Professor at Texas Tech

Riva Dill – was a postdoc at UCSC, now Regulatory Affairs Specialist at Cepheid, San Jose.

Kelly Radecki – scientist at A2 Biotherapeutics

Postdocs

William Oetting (80-82) Professor, University of Minnesota. Now retired.

Timothy Ho (also became research assistant professor UCR) (88-93), Senior Scientist, BioRad. Now retired.

Prem Gupta (91-92) Senior Scientist, USDA, Florida

Kevin Krown (92-94) Professor, San Diego Mesa College; formerly director of Rees Stealy Research Inst., San Diego

Mitsumori Kawaminami (93-94) Professor and Head of Veterinary Medicine, Okayama University, Japan

TianJian Chen (97-98) Associate Professor and Director of Molecular Genetics, Tulane.

Jo-Wen Liu (95-98) Research Associate, Loma Linda University

Wei Wu (98-02) Professor, Capital Medical University, Beijing

Dunyong Tan (02-06) Dean of the Medical School, Jishou University, Hunan, China, now retired.

Eric Ueda (06-07) was Assistant Professor, Sao Paulo, Brazil. Current position unclear.

Tomohiro Yonezawa (2011-2013), Assoc Professor, University of Tokyo, Japan.

KuanHui (Ethan) Chen – Assistant Professor, Texas Tech.

Research Presentations given by Walker (not students/postdocs) since 2005

The interesting biology of phosphorylated prolactin. Tulane University, 2005

Functions of Pseudophosphorylated S179D prolactin. Prolactin Gordon Conference, 2/2006

Dual treatment possibilities with S179D Prolactin and physiological levels of 1,25 dihydroxy vitamin D3, American Association for Cancer Research, 4/2006

Cloning and characterization of a variant of human Stat5a, missing a portion of the N terminal region, with dominant negative effects on the growth of breast cancer cells and beta-casein gene expression. Endocrine Society, 6/2006

S179D Prolactin as a Cancer Therapeutic: Antagonistic Agony, University of Kansas Medical Center. Cancer Anniversary series, 9/2006

S179D Prolactin and Vitamin D3: Collaborators in cell death. Prostate Cancer Foundation Annual Retreat, 10/2006

Effect of pregnancy and lactation on expression of the nuclear hepatocyte nuclear factor 4 alpha in maternal livers, Endocrine Society, 6/2007

Like estradiol, prolactin downregulates estrogen receptor alpha after serine 118 phosphorylation, but uses a different mechanism, Endocrine Society, 6/2007

Cutting edge techniques in pituitary hormone function, International pituitary society meet the professor session, 6/2007

Downregulation of long form prolactin receptor by short form 1b, International pituitary society, 6/2007

Protection against Breast Cancer by Prolactin in milk. California Breast Cancer Research Program Plenary, 9/2007

Anti-cancer potential of phosphorylated prolactin in milk. Susan Love Research Foundation, 10/2007

Evidence suggesting that prolactin functions in the mammary duct. Prolactin Gordon Conference, 2/2008

Evidence suggesting that prolactin functions primarily in the mammary duct except during mid-lactation. Endocrine Society. 6/2008

Nuclear HNF4alpha protein levels decrease postpartum in maternal liver. Endocrine society. 6/2008

Different Prolactin receptors mediate different functions in breast cancer cells suggesting the importance of a short and soluble form to normal breast health. Era of Hope Meeting. Department of Defense Breast Cancer Program. 6/2008

A prolactin binding compound in breast ductal fluids. Dr Susan Love Research Foundation symposium, Santa Monica, 2/2009

Evidence supporting a role for prolactin in the progression of ovarian cancer, AACR, Denver CO, 4/2009

S179D Prolactin blocks estradiol-induced breast cancer cell proliferation in a manner largely duplicated by signaling from the SF1b prolactin receptor, Endocrine Society, Washington DC, 6/2009

Prolactin negates the ability of BRCA1 to increase p21 expression and the ability of already synthesized p21 to inhibit the cell cycle, AACR, Washington DC, 4/2010

A non-prolactin receptor (PRLR), high affinity prolactin binding protein on human milk fat globule membranes, Endocrine Society, San Diego, CA, 6/2010

Effects of prolactin (PRL) and the selective PRL receptor modulator, S179D PRL, on the BRCA1-p21 axis in breast, ovarian and prostate cancer cell lines, Endocrine Society, San Diego, CA, 6/2010-award winning

Targeting the prolactin receptor in cancer therapy: antagonistic agony, Cal State Fullerton, 11/2010

A prolactin-binding compound in breast ductal fluids, Dr Susan Love Research Foundation symposium, Santa Monica, 2/2011

Immune development: role of milk cell transfer and recipient gender, Dept of Physiological Science, UCLA 5/2011

Endocrine Society, Boston MA, 6/2011

Prolactin Antagonists. Arena Pharmaceuticals, 2/2012

Targeting the Prolactin Receptor in Ovarian Cancer. Major symposium talk. Endocrine Society, Houston TX 6/2012

Knockdown of the long prolactin receptor in vivo provides insight into the relative roles of long and short prolactin receptors in the ovary. FASEB summer conference, Snowmass, CO 7/2012

Prolactin inactivates p21 by initiating phosphorylation by pim-1 kinase and the retention of p21 in the cytosol. FASEB summer conference, Snowmass, CO 7/2012

New Therapeutic Approaches for the Prevention and Treatment of Breast Cancer. UCR Wellness presentation 10/2012

Unexpected maternal gifts. Inland Empire Breast Feeding Coalition Meeting, 2/2013

Anti-cancer effects of Antimaia in a highly metastatic, orthotopic, immunologically-competent model of breast cancer. American Association for Cancer Research, Washington DC 4/2013

Antimaia: A new drug therapy. Jishou University Medical School, China 5/2013

Antimaia: Efficacy against highly metastatic breast cancer. Xian University Medical School, China 5/2013

Antimaia: First in a new class of breast cancer therapeutics. California Breast Cancer Research Symposium 5/2013 – award winning

Sexual dimorphism in the immune system develops in the perinatal period. Endocrine Society, San Francisco, 6/2013

Splice form specific targeting of the prolactin receptor. Breast Cancer Coalition, Palo Alto, CA 6/2013

Breast cancer in transgender women. Breast Cancer Coalition, Palo Alto, CA, 8/2013

Unexpected Maternal Gifts. Orange County Breast Feeding Coalition meeting, 2/2014

Anti-metastatic outcome of isoform-specific prolactin receptor targeting. UCR SOM Research retreat. Lake Arrowhead. 10/2014

Anti-metastatic outcome of isoform-specific prolactin receptor targeting. 97th Annual Meeting, Endocrine Society, 3/2015

Transgenerational immune education. University of Tasmania, Australia 10/2015

Role of prolactin in the promotion of breast cancer metastasis. Garvan Institute, Sydney, Australia 10/15

Influence of prolactin on epithelial-immune interactions in health and disease. Keynote. International Symposium on The Pituitary and Related Systems, Hawaii university, Honolulu, HI, 09/20/2016.

There is more of your mother in you than you thought. Inland Empire Breastfeeding Coalition. Riverside, 4/2017

Prolactin and Metastasis: The role of prolactin receptor and T regulatory cells in Breast Cancer Metastasis. FASEB Summer Research Conference, July 23rd-28th, 2017 Steamboat Colorado.

Frank Talamantes: Science and the Man. FASEB Summer Research Conference. Growth hormone and Prolactin in Health and Disease. July 2019, Palm Beach, Florida.

Antimaia: An anti-metastatic therapeutic with multiple anti-cancer activities. City of Hope, October 2019.

Antimaia: First in a New Class of Anti-cancer Therapeutics. Salisbury Award competition. November, 2019, Bethesda MD. Semifinalist.

Antimaia: An anti-metastatic therapeutic with multiple anti-cancer activities. Tech Transfer Talk to Westlake Village BioPartners in UCR Incubator Space. February, 2020

